Office of Innovation and Industry Alliances
Office of Innovation and Industry Alliances
To inquire about our available technologies, call our office (813) 745-6828
| Name & Description | Number |
|---|---|
| FANC: Potentiating Melphalan in Multiple Myeloma by Targeting the Fanconi Anemia/BRCA Resistance Pathway | 03B097 |
| VEGF/PDGF: Orally Bioavailable Small Molecule that Binds VEGF or PDGF for the Treatment of Cancer or Age-Related Macular Degeneration | 03B114 |
| RhoB: Gene Therapy with RhoB Variants to Suppress Cancer Growth | 04B102 |
| STAT3: Enhancing Immune Response to Tumor Cells | 04B112 |
| MRP1: Compounds for Treating Multidrug Resistance | 04MA001 |
| Raf/Mek/P-Erk: Inhibition of the Raf/Mek/P-Erk Pathway by the Beta-2-Adrenergic Receptor Agonist Pirbuterol | 05B072 |
| Src, Abl: Dasatinib on Drug-Eluting Stents for the Prevention and Treatment of Restenosis and Stenosis | 05B111N |
| Shp2: Indoline Scaffold Protein Tyrosine Phosphatase Inhibitors | 06A038 |
| CR-ABBL: Vorinostat co-treatment enhances dasatanib efficacy in CML | 06B078N |
| Rho Kinase: Inhibitors as Novel Anti-Cancer Agents | 06B134 |
| Glut-1: Glucose Transporter Inhibitors Antibodies | 07B083 |
| SHIP: Inhibitors for Treating Graft vs. Host Disease and Transplant Rejection | 08MB010 |
| Topoisomerase II: Inhibitors of Nuclear Export of Topoisomerase II Alpha | 08MB014 |
| Rho Kinase: Pyridylthiazole-Based Ureas As Inhibitors of Rho Associated Protein Kinase (ROCK) | 09MA015 |
| Aurora: Aurora A Kinase Inhibitors | 09MA037 |
| pH: Inhibition of Metastasis with Systemic Non-volatile Buffers | 09MB048 |
| Mcl-1: Asymmetrical Marinopyrroles as Anti-Cancer Agents | 10MA018N |
| LPAAT: Lysophosphatidic Acid Acyltransferase-Beta Inhibitors to Treat Pancreatic Cancer | 10MA019N |
| FT/GGT: Farnesyltransferase/ Geranylgeranyltransferase Dual Inhibitor | 10MB048 |
| Topoisomerase II: Inhibitor Enhancer in Multiple Myeloma | 10MB078 |
| Proteasome: Non-covalent and Reversible Proteasome Inhibitors with an Oxadiazole-isopropylamide Core | 10MB083 |
| HDAC6: Novel Small Molecule Histone Deacetylase 6 Inhibitor with a Substituted Aryl Urea Cap Group | 12MA030 |
| Mcl-1/Bcl-xL: Cyclic, Symmetrical and Asymmetrical Marinopyrroles as Anti-Cancer Agents | 12MA035N |
| IRE-1: Novel Small Molecule Inhibitors of IRE-1 for Treatment of B-cell Cancer | 12MB089 |
| STAT3: STAT3 Dimerization Inhibitors | 12MB098 |
| Anti-infectives: Symmetrical Synthetic Marinopyrroles as anti-MRSA Therapeutics | 12MB110 |
| BRD4 JAK2: Novel BRD4/JAK2 Dual Inhibitors as Cancer Therapeutics | 14MB069 |
| WEE1: Small molecule WEE1 inhibitor to treat cancer that inhibits WEE1 phosphorylation of H2B but not Cdc2 | 14MB092N |
| Ras: Inhibitors of the Binding of GTP to Oncogenic Mutant K-Ras | 15MA011 |
| Ras/Raf: Stapled Peptides Designed to Inhibit the K-Ras/Raf Interaction | 15MA012 |
| Aurora/JAK2: Dual JAK2 and Aurora A Kinase Inhibitor for GVHD Prophylaxis | 16MA005N |
| β-catenin/BCL-9: Small molecule inhibitors of the interaction of β-catenin and T-cell Factor | 17MA014 |
| β-catenin/TCF: Small molecule inhibitors of the interaction of β-catenin and T-cell Factor | 17MB040N |
| XBP-1: XXBP-1 Inhibitor B-I09 for the Treatment of Acute GVHD and Solid Organ Rejection | 17MB051 |